Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ALNY's Cash to Debt is ranked higher than
97% of the 830 Companies
in the Global Biotechnology industry.

( Industry Median: 56.40 vs. ALNY: No Debt )
ALNY' s 10-Year Cash to Debt Range
Min: 3.29   Max: No Debt
Current: No Debt

Equity to Asset 0.92
ALNY's Equity to Asset is ranked higher than
88% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ALNY: 0.92 )
ALNY' s 10-Year Equity to Asset Range
Min: -0.99   Max: 0.92
Current: 0.92

-0.99
0.92
Interest Coverage No Debt
ALNY's Interest Coverage is ranked higher than
95% of the 382 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALNY: No Debt )
ALNY' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 47.26
M-Score: 31.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -309.32
ALNY's Operating margin (%) is ranked lower than
67% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. ALNY: -309.32 )
ALNY' s 10-Year Operating margin (%) Range
Min: -14236.93   Max: -28.95
Current: -309.32

-14236.93
-28.95
Net-margin (%) -263.43
ALNY's Net-margin (%) is ranked lower than
65% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -71.50 vs. ALNY: -263.43 )
ALNY' s 10-Year Net-margin (%) Range
Min: -14223.3   Max: -27.3
Current: -263.43

-14223.3
-27.3
ROE (%) -15.31
ALNY's ROE (%) is ranked higher than
59% of the 754 Companies
in the Global Biotechnology industry.

( Industry Median: -27.51 vs. ALNY: -15.31 )
ALNY' s 10-Year ROE (%) Range
Min: -336.03   Max: -13.08
Current: -15.31

-336.03
-13.08
ROA (%) -13.79
ALNY's ROA (%) is ranked higher than
58% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -23.16 vs. ALNY: -13.79 )
ALNY' s 10-Year ROA (%) Range
Min: -97.61   Max: -5.01
Current: -13.79

-97.61
-5.01
ROC (Joel Greenblatt) (%) -996.54
ALNY's ROC (Joel Greenblatt) (%) is ranked lower than
61% of the 805 Companies
in the Global Biotechnology industry.

( Industry Median: -344.23 vs. ALNY: -996.54 )
ALNY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2120.98   Max: -168.68
Current: -996.54

-2120.98
-168.68
Revenue Growth (3Y)(%) -29.60
ALNY's Revenue Growth (3Y)(%) is ranked lower than
75% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. ALNY: -29.60 )
ALNY' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 108
Current: -29.6

0
108
EBITDA Growth (3Y)(%) 65.40
ALNY's EBITDA Growth (3Y)(%) is ranked higher than
95% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. ALNY: 65.40 )
ALNY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -64.8   Max: 65.4
Current: 65.4

-64.8
65.4
EPS Growth (3Y)(%) 52.80
ALNY's EPS Growth (3Y)(%) is ranked higher than
92% of the 408 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. ALNY: 52.80 )
ALNY' s 10-Year EPS Growth (3Y)(%) Range
Min: -66.7   Max: 52.8
Current: 52.8

-66.7
52.8
» ALNY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ALNY Guru Trades in Q2 2014

Vanguard Health Care Fund 4,973,900 sh (+9.93%)
George Soros Sold Out
Jim Simons Sold Out
Columbia Wanger 784,500 sh (-13.10%)
» More
Q3 2014

ALNY Guru Trades in Q3 2014

Steven Cohen 12,100 sh (New)
Vanguard Health Care Fund 5,277,100 sh (+6.10%)
Pioneer Investments 324,287 sh (unchged)
Columbia Wanger 554,000 sh (-29.38%)
» More
Q4 2014

ALNY Guru Trades in Q4 2014

John Griffin 430,000 sh (New)
Paul Tudor Jones 3,540 sh (New)
Bill Frels 2,200 sh (New)
Pioneer Investments 483,213 sh (+49.01%)
Steven Cohen Sold Out
Vanguard Health Care Fund 5,030,100 sh (-4.68%)
Columbia Wanger 477,700 sh (-13.77%)
» More
Q1 2015

ALNY Guru Trades in Q1 2015

Louis Moore Bacon 5,500 sh (New)
Julian Robertson 161,600 sh (New)
John Griffin 960,000 sh (+123.26%)
Vanguard Health Care Fund 6,094,810 sh (+21.17%)
Pioneer Investments 484,824 sh (+0.33%)
Bill Frels 2,200 sh (unchged)
Paul Tudor Jones Sold Out
Columbia Wanger 402,500 sh (-15.74%)
» More
» Details

Insider Trades

Latest Guru Trades with ALNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 23.64
ALNY's Forward P/E is ranked lower than
55% of the 182 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. ALNY: 23.64 )
N/A
P/B 7.20
ALNY's P/B is ranked lower than
95% of the 713 Companies
in the Global Biotechnology industry.

( Industry Median: 3.32 vs. ALNY: 7.20 )
ALNY' s 10-Year P/B Range
Min: 1.58   Max: 21.38
Current: 7.2

1.58
21.38
P/S 163.80
ALNY's P/S is ranked lower than
129% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: 7.28 vs. ALNY: 163.80 )
ALNY' s 10-Year P/S Range
Min: 3.09   Max: 189.72
Current: 163.8

3.09
189.72
Current Ratio 13.51
ALNY's Current Ratio is ranked higher than
84% of the 805 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. ALNY: 13.51 )
ALNY' s 10-Year Current Ratio Range
Min: 1.88   Max: 13.51
Current: 13.51

1.88
13.51
Quick Ratio 13.51
ALNY's Quick Ratio is ranked higher than
84% of the 805 Companies
in the Global Biotechnology industry.

( Industry Median: 4.07 vs. ALNY: 13.51 )
ALNY' s 10-Year Quick Ratio Range
Min: 1.88   Max: 13.51
Current: 13.51

1.88
13.51
Days Sales Outstanding 60.65
ALNY's Days Sales Outstanding is ranked higher than
51% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: 61.41 vs. ALNY: 60.65 )
ALNY' s 10-Year Days Sales Outstanding Range
Min: 0.57   Max: 288.31
Current: 60.65

0.57
288.31

Valuation & Return

vs
industry
vs
history
Price/Net Cash 11.50
ALNY's Price/Net Cash is ranked lower than
99% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. ALNY: 11.50 )
ALNY' s 10-Year Price/Net Cash Range
Min: 3.7   Max: 92.77
Current: 11.5

3.7
92.77
Price/Net Current Asset Value 11.40
ALNY's Price/Net Current Asset Value is ranked lower than
99% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. ALNY: 11.40 )
ALNY' s 10-Year Price/Net Current Asset Value Range
Min: 3.54   Max: 82.06
Current: 11.4

3.54
82.06
Price/Tangible Book 7.20
ALNY's Price/Tangible Book is ranked lower than
97% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALNY: 7.20 )
ALNY' s 10-Year Price/Tangible Book Range
Min: 2.64   Max: 15.17
Current: 7.2

2.64
15.17
Price/DCF (Projected) 87.00
ALNY's Price/DCF (Projected) is ranked lower than
162% of the 151 Companies
in the Global Biotechnology industry.

( Industry Median: 2.40 vs. ALNY: 87.00 )
ALNY' s 10-Year Price/DCF (Projected) Range
Min: 1.98   Max: 83.21
Current: 87

1.98
83.21
Price/Median PS Value 7.80
ALNY's Price/Median PS Value is ranked lower than
138% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. ALNY: 7.80 )
ALNY' s 10-Year Price/Median PS Value Range
Min: 0.16   Max: 7.03
Current: 7.8

0.16
7.03
Earnings Yield (Greenblatt) -2.00
ALNY's Earnings Yield (Greenblatt) is ranked higher than
63% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: -4.40 vs. ALNY: -2.00 )
ALNY' s 10-Year Earnings Yield (Greenblatt) Range
Min: -6   Max: 1781.6
Current: -2

-6
1781.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:DUL.Germany,
Alnylam Pharmaceuticals Inc was originally incorporated in Delaware under the name Alnylam Holding Co. on May 8, 2003. It is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The Company's research and development is focused primarily on use of its proprietary N-acetylgalactosamine, or GalNAc-conjugate for delivery of small interfering RNAs, or "siRNAs" — the molecules that mediate RNAi — toward liver-expressed genes involved in the cause or pathway of human diseases. It is also focused on clinical indications where there are high unmet medical needs, early biomarkers for the assessment of clinical activity in Phase 1 clinical studies, and a definable path for drug development, regulatory approval and commercialization. The Company operates in a single reporting segment, the discovery, development and commercialization of RNAi therapeutics. Its competitors include Takeda, Kyowa Hakko Kirin, Marina Biotech, Inc., Arrowhead and its subsidiary, Calando Pharmaceuticals, Inc., or Calando, Quark Pharmaceuticals, Inc., or Quark, Silence Therapeutics plc, Tekmira, Sylentis, S.A.U., or Sylentis, Dicerna Pharmaceuticals, Inc. and Arcturus Therapeutics, among others. The research, testing, manufacture and marketing of drug products and their delivery systems are extensively regulated in the United States and the rest of the world.
» More Articles for ALNY

Headlines

Articles On GuruFocus.com
Arrowhead Research Making Headway In The RNAi Therapy Platform Mar 09 2015 
comment on ALNY Mar 09 2013 
comment on ALNY Mar 02 2013 
Weekly CEO Buys Highlight: ULBI, BDE, ALNY, CTTR, GFN Feb 27 2012 
Weekly CEO Buys Highlight: VITC, CTFO, RPM, EFC, ALNY Oct 17 2011 
Alnylam Pharmaceuticals Reports Second Quarter 2009 Financial Results Aug 06 2009 
Alnylam to Webcast Conference Call Discussing Fourth Quarter and 2008 Financial Results Feb 17 2009 

More From Other Websites
4 Big Biotech Companies to Sell Now May 26 2015
Alnylam Initiates Phase 1 Clinical Trial for ALN-AS1, an Investigational RNAi Therapeutic Targeting... May 26 2015
Alnylam Initiates Phase 1 Clinical Trial for ALN-AS1, an Investigational RNAi Therapeutic Targeting... May 26 2015
Alnylam's Cardiac Amyloidosis Drug Gets Orphan Status - Analyst Blog May 22 2015
Alnylam Receives Orphan Drug Designation from the United States Food & Drug Administration for... May 20 2015
Alnylam Receives Orphan Drug Designation from the United States Food & Drug Administration for... May 20 2015
Alnylam Files Clinical Trial Application for ALN-AAT - Analyst Blog May 18 2015
Alnylam Files Clinical Trial Application (CTA) for ALN-AAT, an Investigational RNAi Therapeutic for... May 17 2015
Alnylam Files Clinical Trial Application (CTA) for ALN-AAT, an Investigational RNAi Therapeutic for... May 17 2015
After-Hours Movers Friday: Seventy Seven Energy, Kite Pharma May 16 2015
ALNYLAM PHARMACEUTICALS, INC. Financials May 15 2015
10-Q for Alnylam Pharmaceuticals, Inc. May 11 2015
Alnylam's Q1 Loss Narrower than Expected, Confirms Guidance - Analyst Blog May 08 2015
ALNYLAM PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report May 08 2015
Alnylam reports 1Q loss May 07 2015
Alnylam reports 1Q loss May 07 2015
Alynlam Pharmaceuticals (ALNY) Stock Falls in After-Hours Despite Better Than Expected Earnings May 07 2015
Alnylam Pharmaceuticals Reports First Quarter 2015 Financial Results and Highlights Recent Period... May 07 2015
ALNYLAM PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... May 07 2015
Alnylam Pharmaceuticals Reports First Quarter 2015 Financial Results and Highlights Recent Period... May 07 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK